WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Carrum Health
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Biomeme | August 20, 2020
Biomeme, Inc. announced today that the U.S. Food and Drug Administration (FDA) gave Biomeme’s SARS-CoV-2 Real-Time RT-PCR Test Emergency Use Authorization (EUA) for use in any lab CLIA-certified to perform high complexity testing. It is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The Biomeme SARS-CoV-2 Real-Time RT-PCR Test is designed to detect the virus&r...
Industrial Impact
O2 Investment Partners ( | January 24, 2022
O2 Investment Partners announced that it has partnered with Modular Devices, Inc. and its President & CEO, Greg Mink, to support the Company’s continued growth. Terms of the deal were not disclosed. Founded in 1987, Modular Devices, Inc. is a leading provider of mobile and modular medical imaging equipment labs and cleanroom solutions throughout the United States. MDI’s medical imaging solutions offer various imaging modalities through short- and long-term leases t...
Siemens | June 11, 2020
Siemens, a process automation specialist, and Exyte, a biopharmaceutical manufacturing facility provider, have joined forces to offer end-to-end solutions for the biopharmaceutical industry.Against the background of the current challenges associated with the Covid-19 pandemic, pharmaceutical companies are facing challenges in developing and mass-producing new vaccines and medicines in existing production facilities. Siemens and Exyte are committed to tackle those challenges. Together, they...
Cell and Gene Therapy
Eiger BioPharmaceuticals, Inc. | October 06, 2022
Eiger BioPharmaceuticals, Inc. a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today announced that, following feedback from the U.S. Food and Drug Administration the company will not submit an emergency use authorization application of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19. Following Eiger's press release on September 6, 2022, the c...
Cell and Gene Therapy, Medical
Video
Industrial Impact, Medical
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE